STRO-002-GM2: A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (clinicaltrials.gov) - Nov 7, 2024 - P1 | N=58 | Recruiting | Sponsor: Sutro Biopharma, Inc. | Active, not recruiting ➔ Recruiting
Combination therapy • Enrollment open • Metastases • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor
|